US20100272796A1 - Sustained release aminopyridine composition - Google Patents

Sustained release aminopyridine composition Download PDF

Info

Publication number
US20100272796A1
US20100272796A1 US12/626,085 US62608509A US2010272796A1 US 20100272796 A1 US20100272796 A1 US 20100272796A1 US 62608509 A US62608509 A US 62608509A US 2010272796 A1 US2010272796 A1 US 2010272796A1
Authority
US
United States
Prior art keywords
aminopyridine
sustained release
composition
mg
release composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/626,085
Inventor
Sean Cunningham
Seamus Mulligan
Michael Myers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alkermes Pharma Ireland Ltd
Original Assignee
Sean Cunningham
Seamus Mulligan
Michael Myers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US52859303P priority Critical
Priority to US52859203P priority
Priority to US52876003P priority
Priority to US56089404P priority
Priority to US11/010,828 priority patent/US8007826B2/en
Application filed by Sean Cunningham, Seamus Mulligan, Michael Myers filed Critical Sean Cunningham
Priority to US12/626,085 priority patent/US20100272796A1/en
Publication of US20100272796A1 publication Critical patent/US20100272796A1/en
Assigned to ELAN PHARMA INTERNATIONAL LIMITED reassignment ELAN PHARMA INTERNATIONAL LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MULLIGAN, SEAMUS, CUNNINGHAM, SEAN, MYERS, MICHAEL
Assigned to MORGAN STANLEY SENIOR FUNDING, INC. reassignment MORGAN STANLEY SENIOR FUNDING, INC. PATENT SECURITY AGREEMENT (SECOND LIEN) Assignors: ALKERMES CONTROLLED THERAPEUTICS INC., ALKERMES PHARMA IRELAND LIMITED, ALKERMES, INC.
Assigned to MORGAN STANLEY SENIOR FUNDING, INC. reassignment MORGAN STANLEY SENIOR FUNDING, INC. PATENT SECURITY AGREEMENT (FIRST LIEN) Assignors: ALKERMES CONTROLLED THERAPEUTICS INC., ALKERMES PHARMA IRELAND LIMITED, ALKERMES, INC.
Assigned to EDT PHARMA HOLDINGS LIMITED reassignment EDT PHARMA HOLDINGS LIMITED ASSET TRANSFER AGREEMENT Assignors: ELAN PHARMA INTERNATIONAL LIMITED
Assigned to EDT PHARMA HOLDINGS reassignment EDT PHARMA HOLDINGS NOTICE OF CHANGE IN REGISTERED OFFICE ADDRESS Assignors: EDT PHARMA HOLDINGS
Assigned to ALKERMES PHARMA IRELAND LIMITED reassignment ALKERMES PHARMA IRELAND LIMITED CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: EDT PHARMA HOLDINGS LIMITED
Assigned to ALKERMES PHARMA IRELAND LIMITED reassignment ALKERMES PHARMA IRELAND LIMITED NOTICE OF CHANGE IN REGISTERED OFFICE ADDRESS Assignors: ALKERMES PHARMA IRELAND LIMITED
Assigned to ALKERMES, INC., ALKERMES CONTROLLED THERAPEUTICS INC., ALKERMES PHARMA IRELAND LIMITED reassignment ALKERMES, INC. RELEASE BY SECURED PARTY (SECOND LIEN) Assignors: MORGAN STANLEY SENIOR FUNDING, INC.
Assigned to WILMINGTON TRUST, NATIONAL ASSOCIATION reassignment WILMINGTON TRUST, NATIONAL ASSOCIATION SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ACORDA THERAPEUTICS, INC., CIVITAS THERAPEUTICS, INC.
Application status is Abandoned legal-status Critical

Links